Telix Pharmaceuticals Teams Up For Personalised Radiopharmaceutical Therapy Via QDOSE

In a significant move within the biopharmaceutical sector, Australian-based Telix Pharmaceuticals has announced a strategic partnership with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft and Quantinm. This collaboration is set to commercially integrate the QDOSE dosimetry software platform into Telix's operations. QDOSE, a validated software platform, is designed for the reliable estimation of patient-specific dosimetry across both therapeutic and diagnostic radiopharmaceuticals. This integration marks a pivotal step towards developing personalised treatment regimens within Telix's therapeutic radiopharmaceutical programs and clinical collaborations.

QDOSE's capabilities extend to supporting dosimetry calculations using various imaging techniques, alongside providing essential tools for attenuation and background correction. Telix's strategy involves leveraging QDOSE in tandem with its artificial intelligence (AI) products. This approach aims to offer a comprehensive tool for clinicians and third-party commercial drug developers. Notably, QDOSE has already received regulatory clearance in the US and is marked for clinical use within the European Union.

Under the terms of the agreement, Telix will compensate with undisclosed royalties and fees on product sales. This partnership is expected to elevate QDOSE to an industry standard in dosimetry analysis, a critical component in nuclear medicine for calculating the absorbed dose of radiation received by different parts of the body. The integration of QDOSE into Telix's framework is anticipated to significantly contribute to the advancement of personalised radiopharmaceutical therapy. Such advancements hold promise for improving clinical outcomes by optimising treatment response, reducing effects on healthy organs, and enhancing isotope supply chain utilisation.

Telix Pharmaceuticals, headquartered in Melbourne, Australia, operates on a global scale with activities spanning across the US, Europe, and Japan. The company focuses on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals alongside associated medical devices. Among its leading products is the gallium-68 gozetotide injection, which has garnered regulatory approvals in key markets including the US, Australia, and Canada. Telix's product portfolio is dedicated to addressing unmet medical needs in oncology and rare diseases, positioning itself as a key player in the biopharmaceutical industry.

The collaboration between Telix Pharmaceuticals, ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft, and Quantinm through the integration of QDOSE represents a forward-thinking approach to enhancing radiopharmaceutical therapy. By focusing on personalised treatment regimens and leveraging advanced technologies such as AI, this partnership underscores a commitment to improving patient care in oncology and beyond.